<DOC>
	<DOCNO>NCT01291810</DOCNO>
	<brief_summary>The safety immunogenicity TNFα-Kinoid ( TNF-K ) evaluate phase I-II clinical study conduct subject Crohn 's Disease ( CD ) . Preliminary result clinical efficacy promising . The principal aim present study confirm clinical efficacy TNF-K subject moderate severe CD . Subjects secondary resistance intolerance anti-TNFα monoclonal antibody enrol trial . In addition , immune response safety elicit TNF-K also evaluate .</brief_summary>
	<brief_title>Clinical Efficacy TNFa Kinoid Crohn 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Male female age 18 65 year , inclusive . 2 . Have diagnosis Crohn 's disease least 6 month . 3 . Moderate severe active Crohn 's disease define Crohn 's Disease Activity Index ( CDAI ) score ≥ 220 ≤ 450 , presence colonic mucosal ulceration least 2 segment , ulceration ≥ 10 % mucosal surface one segment involve . 4 . Have develop secondary resistance antiTNFα therapy . 1 . Primary nonresponse previously receive treatment direct TNFα Or Intolerance related primary pharmacological effect antiTNFα instance , limited , severe opportunistic infection demyelinate autoimmune disease . 2 . History severe systemic bacterial , fungal , viral , parasitic infection within 3 month prior screen ; occurrence acute infection within 2 week first administration study drug . 3 . Treatment immunosuppressive immunomodulatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>